Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Advanced Pharmacology > Neuro Pt 3 Depression, Schizophrenia, Bipolar Disorder > Flashcards

Neuro Pt 3 Depression, Schizophrenia, Bipolar Disorder Flashcards

1
Q

Depression

  • Definition:
    • Depressed mood most of the time for > __ weeks and/or loss of ____ or _____ in most activities
  • DSM V Criteria: __ or more (must include the first 2)
    • _____
    • _____
    • Change in w____ or a____
    • I____ or hyper_____
    • Psychomotor r_____ or a______
    • Loss of e____ or f_____
    • ___lessness or g____
    • Impaired con_____ or in______
    • Thought of d____ or ______ ideation or suicide _____
A
  • Definition
    • 2, interest, pleasure
  • 5
    • Depressed mood
    • Loss of interest or pleasure
    • weight, appetite
    • insomnia, hypersomnia
    • retardation, agitation
    • energy, fatigue
    • worthlessness, guilt
    • concentration, indecisiveness
    • death, SI, attempt
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pathophysiology of Depression

  • Hypotheses
    • Neurotrophic - brain derived neurotrophic factor (BDNF) _____
    • Neurotransmitters - deficiency of (3)
    • Neuroendocrine - hormonal imbalances of (2)
  • Genetic factors account for up to 50% of depression
  • Treatment
    • _____ amount of neurotransmitter available at the synaptic clef (noradrenergic, serotoninergic)
      • _____ rate at which neurotransmitter is taken back up into presynaptic neuron
      • _______ neurotransmitter’s metabolic degradation
A
  • Hypothesis
    • Deficiency
    • Serotonin (5HT), Norepinephrine (NE), Dopamine (DA)
    • Estrogen, Testosterone
  • Tx
    • Increase
      • Decrease
      • Inhibit

BDNF is a protein in our brain that helps the growth of neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Treatment for Depression

(5)

A
  • Tricyclic Antidepressants (TCAs)
  • Monamine oxidase Inhibitors (MAOIs)
  • Selective-serotonin reuptake inhibitors (SSRIs)
  • Selective-norepinephrine reuptake inhibitors (SNRIs)
  • Others (miscellaneous)
    • Buproprion (Wellbutrin)

List in order of discovery, worked on AE when making new drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Time of Onset

  • How long does it take to reach full effect of medication?
  • 1-2 wks
    • Improved ____
    • Reduced _____
  • 1-3 wks
    • Improved ____, _____
    • Increased ____ level, ____ level
  • 2-4 wks
    • Improved ____
    • Reduced ____
A
  • 4-6 weeks (counselling!!)
  • 1-2 wks
    • sleep
    • anxiety
  • 1-3 wks
    • self-care, concentration
    • energy, activity
  • 2-4 wks
    • mood
    • suicidal ideation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Tricyclic Antidepressants (TCA)

Indication

  • _____ available (prior to 1980s and discovery of SSRIs)
    • Today reserved for _____ disease
A
  • earliest
    • refractory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

TCA

MOA

  • ________ inhibition of ______ and _____ ______ (allows for increased NE to bind to receptors at synaptic cleft)
  • Secondary amines more ____ for ___ (potency)
  • Other receptor effects:
    • a1-adrenergic blockade - (1)
    • Histamine 1 receptor (1)
    • Anticholinergic (2)
    • Sodium and calcium channel blockade (1)
A
  • Non-selective inhibition of norepinephrine (NE) and serotonin (5HT) reuptake
  • selective for NE
    • orthostatic hypotension
    • sedation
    • dry mouth, constipation
    • cardiotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

TCA

Tertiary Amines (2)

Secondary Amines (1)

Prevalence of use?

A
  • Tertiary Amines
    • Amitriptyline (Elavil)
    • Doxepin (Sinequan)
  • Secondary Amines​ -> Lack active metabolites and have linear kinetics (wide therapeutic window)
    • ​Nortriptyline (Pamelor)
  • First class of antidepressant medications available, however, side effects have limited their use

Secondary amines are the newer group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

TCA

AE (5)

A
  • Antihistamine (sedation, weakness, fatigue)
  • Anticholinergic (dry mouth, blurred vision, constipation, urinary retention)
  • a1-receptor blockade (hypotension)
  • Sodium channel blockade (arrhythmias, QTc prolongation)
  • Other (sexual dysfunction, seizure potential, weight gain, photosensitivity, hepatotoxicity, withdrawal if stopped abruptly (titrate slowly))
  • BC its SO NONSELECTIVE - it causes all these AE*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TCA

Drug Interactions (3)

A
  • MAOI
    • MAOIs inhibit the breakdown of neurotransmitters (dopamine, serotonin, norepinephrine)
      • HTN, tachycardia, confusion, seizures
      • Serotonin syndrome
  • SSRIs - may lead to Serotonin Syndrome
  • Alcohol and other CNS depressants
    • ​Additive effects (drowsiness, diziness)
    • Worsen depression

Almost never given with any other antidepressant - don’t really see combinations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Monamine Oxidase Inhibitors (MAOIs)

Indication

A

Due to potential serious adverse effects from drug and food interactions, NOT used as first line therapy (more for refractory)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MAOI

MOA

A

Irreversible inhibition of monamine oxidase (1-2 wks to restore)

Responsible for metabolism of NE, 5HT, Dopamine within the neuronal synapse

MAO-A - nonselective (NE, 5HT)

MAO-B - selective for dopamine

In depression, we do the opposite of PD where we use lower doses - we want higher doses to target the NE and 5HT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MAOI

Agents

A

Selegiline (Emsam)

(non-selective inhibits both MAO-A and B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MAOI

Significant AE

A
  • Postural Hypotension
  • Hypertensive Crisis (food interaction)
  • Sleep disturbances
  • Weight gain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MAOI

Significant Drug Interactions

Drug-Food Interactions

A
  • TCAs
  • SSRIs
  • Sympathomimetic agents (cocaine)
  • Linezolid (abx) - also has MAOI properties so you can see additive effects of blocking those
  • MAO inhibition may persist up to 10-14 days following discontinuation (remember irreversibly binds)
  • Tyramine content (aged cheeses, meats, yeast extract, red wine) Bananas, dried fruits
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Selective Serotonin Reuptake Inhibitors (SSRIs)

Indication

A

Targeted the results of TCAs without the histamine/cholinergic/adrenoceptor properties

GOLD STANDARD DRUG OF CHOICE*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

SSRI

MOA

A

Blocks serotonin transporter (SERT)

  • Blocking reuptake of 5HT into presynaptic neuron = increased circulating 5HT for post synaptic uptake
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

SSRI

Agents

A

Late 1980s

Fluoxetine (Prozac, Prozac weekly)

Paroxetine (Paxil, Paxil CR)

Sertraline (Zoloft)

Fluvoxamine (Luvox)

Citalopram (Celexa)

Escitalopram (Lexapro)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

SSRI

Fluoxetine

Half life?

Active Metabolites?

A
  • ~5 days (requires 5 week washout)
  • YES

Remember, takes about 5 half lives for drug to be eliminated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

SSRI

AE

  1. CNS
  2. CV
  3. Hematologic
  4. GI
  5. Sexual Dysfunction
  6. Weight gain
  7. Withdrawal syndrome (4)

  • Incidence of orthosatic hypotension, sedation, anitcholinergic SE, and CV effects are significantly less than ____
A
  1. Fluoxetine - activating (insomnia) take in the morning, Paroxetine - sedating take at night so not tired all the time
  2. QT prolongation with citalopram and escitalopram
  3. Increased risk for bleeding (esp w ASA, NSAIDs, anticoag)
  4. N/V, diarrhea (GI effects more early on esp if started with high dose thats why we start slow and titrate up)
  5. SSRIs have highest incidence
  6. Paroxetine > all others
  7. GI complaints, flu-like symptoms, anxiety, insomnia (if abruptly dc’d)
  • TCAs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

SSRI

Drug Interactions (3)

  • Timing if converting between SSRIs and MAOIs
    • *fewest drug interactions with (3)
A

MAOIs, TCAs, Linezolid (has MAO inhibition)

  • Wait up to 5 weeks after stopping (Fluoxetine) SSRI before starting MAO
  • Wait 2 weeks after stopping MAOI before starting SSRI
    • citalopram, escitalopram, sertraline
  • ex) if pt on SSRI and admitted for infection and given linezolid = given together can cause hypertensive crisis/serotonin syndrome*
  • UP to 5 weeks since other ones take shorter to clear*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

AB is a 33 yo F started on fluoxetine (Prozac) for depression. Fluoxetine has a half life of ________, should be taken in the ______, and is known to cause _____ side effects when compared to amitriptyline

  • 24 hrs, morning, less
  • 24 hrs, evening, less
  • 5 days, morning, less
  • 5 days, evening, less
  • 5 days, morning, more
A

5 days, morning, less

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Serotonin Syndrome

A

Life threatening central excitatory syndrome rd INCREASE serotonin

  • Hyperthermia, confusion, agitation, autonomic hyperactivity, myoclonus, hyperreflexia, diaphoresis, tremor, diarrhea, neuromuscular abnormalities, ocular clonus
  • Tx: stop + supportive care
  • Non antidepressant meds associated (anti-emetics, dextromethorphan, fentanyl, linezolid, meperidine, serotonin agonists sumatriptan, tramadol, valproic acid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Buproprion (Wellbutrin)

Indications

MOA

Route

Pharmacokinetics

Significant AE (3)

A
  • Adjunctive tx for depression
  • Blocks reuptake of dopamine and norepinephrine
  • PO only
  • Hepatically metabolized through CYP2D6
  • Lowers seizure threshold (high doses/abrupt withdrawal), Activating (tremor, insomnia), No sexual dysf/weight gain
  • The newer the drugs the MOA gets shmancy*
  • Doesn’t touch serotonin - also used off label for smoking cessation so if pt has both can help both*
  • However if pt suffers from epilepsy don’t want to use bc lowers seizure threshold*
  • Just know its a SUBSTRATE of CYP - so if given with inducer may lower serum levels*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Selective Norepinephrine Reuptake Inhibitors (SNRIs)

MOA

A

Bind to serotonin (SERT) and norepinephrine (NET) transporters

  • prevents reuptake of both 5HT and NE (selective for NE)
25
Q

SNRI

Route

A

All PO

26
Q

SNRI

Agents

A

Venlafaxine (Effexor) - Immediate and ER

Desvenlafaxine (Pristiq)- ER

Duloxetine (Cymbalta)

Miilnacipran (Savella)

27
Q

SNRI

Significant AE

A
  • Hypertension (NE)
  • Sexual Dysfunction
  • Insomnia (take in morning)
  • Nausea
  • NOREPI-so all flight or flight AE- take in morning*
  • Sexual dysfunction bc again too much 5HT effects release of some hormones*
28
Q

Boxed Warning for All Antidepressants

- Important to monitor pts for failure to ____ or ____ sx of depression when these drugs are ___ or dose is _____

A

Antidepressants increase risk of SUICIDAL THINKING and BEHAVIOR in children, adolescents, and young adults (18-24yo) with major depressive disorder and other psychiatric disorders

  • respond, worsening, started, increased
  • Bc takes time to work and they are stimulating, gives ppl the strength to commit suicide while suicidal ideation not yet gone away*
29
Q

Management of Depression

  1. ​Antidepressant pharmacotherapy initiated, follow up in __ weeks

  • For partial or no response what do you do?
  • For full response what do you do?

  1. Assess response __-__ weeks

  • For partial or no response what do you do?
  • For full response what do you do?
A
  1. 2 weeks
    • ​​Assess adherance-Increase doseif clinically indicated and no issues with tolerability -Consider ECT for severe symptoms
    • Maintain treatment if no issues with tolerability
  2. 4-6 weeks
    • ​Increase dose OR Change to alternative antidepressant in same class OR Change/Augment psychotherapy OR Consider ECT
    • Move to continuation phase

Assessing adherence = always first step - esp in neuropsych disorders ppl more prone to noncompliance - may have negative attitudes toward med/too expensive

30
Q

Depression in Pregnancy

  • Reported in __-__% of pregnant women
  • Mild to moderate depression
    • _____ pharmacotherapy unless ____ hx
    • _____/_____ FIRST LINE
  • Severe depression
    • _____/____ pharmacotherapy
      • Which drug is safest? Less likely to cross into breast milk?
      • Which drugs to for sure avoid bc causes birth defects?
        • If previously failed multiple therapies, okay to continue
A
  • 14-23%
    • discontinue, severe
    • CBT/interpersonal psychotherapy
    • Initiate/continue
      • Sertraline
      • Paroxetine/Fluoxetine

Really try not to use antidep bc teratogenic

31
Q

Which of the following is an MAOI used to treat depression?

  • Sertraline (Zoloft)
  • Notriptyline (Pamelor)
  • Seligiline (Emsam)
  • Fluvoxamine (Luvox)
A

Seligiline (Emsam)

32
Q

Schizophrenia

“to split” “mind”

  • _____ characterized by a clear sensorium but a marked thinking disturbance
  • Typical onset:
  • Diagnosis
    • Reduced _____ + __ of any _____ or ____ symptoms
    • Persistent for at least ___ months
  • Not necessarily ______
A
  • Psychosis
  • Late adolescence, early adulthood
    • functioning, 2 of positive or negative
    • 6
  • violent
33
Q

Schizophrenia Positive Symptoms

Definition

  • D_______
  • H_______
  • Disorganized ____
  • Unusual _____
  • Ho_____
  • Ex_____
  • G_____
A

Acute episodes of psychosis “positive symptoms”, often accompanied by a decline in overall functioning over time secondary to “negative symptoms”

  • Delusions
  • Hallucinations
  • speech
  • behavior
  • Hostility
  • Excitement
  • Gradiosity
34
Q

Schizophrenia Negative Symptoms

  • _____ affect
  • Lack of m_____ and p_____
  • _____ withdrawal
  • Un_____ness
  • _____ withdrawal
  • Poverty of ______
A
  • Blunted
  • motivation, pleasure
  • Emotional
  • Uncooperativeness
  • Social
  • Speech

Negative = lacking

35
Q

Neurotransmitter Hypotheses of Schizophrenia

  • Pathophysiology remains ________, but thought to be related to complex neurotransmitter alterations
  • Dopamine receptor _____
    • Dopamine hyperactivity (caudate nucleus)
      • _____ symptoms
    • Dopamine hypoactivity (frontotemporal regions)
      • _____ symptoms and _____ dysfunction
  • Serotonin receptros (5HT-2a)
    • Present on dopaminergic axons
    • ______ 5HT concentrations found in schizophrenia
    • Receptor responsible for regulation of glutamate, NE, DA, stabilizing NMDA receptor, GABA
A
  • unknown
  • defect
    • positive
    • negative, cognitive
  • 5HT2
    • Higher

In general we treat shiz by blocking dopamine and 5HT (serotonin)

36
Q

Antipsychotic Drugs

MOA (2)

Which one alleviates positive and which one alleviates negative?

A
  • Dopamine receptor blockers inhibit the release of DA and thereby alleviate positive symptoms
  • Serotonin (5HT2) receptor agonist/antagonist** can alleviate **negative symptoms of schizophrenia
37
Q

Antipsychotic Drug Sx Relief

Counsel on duration to symptom relief

  • Initially:
  • 2-8 wks:
  • Late > 8 wks:
A
  • aggression
  • attention, anxiety, socialization
  • hallucinations, disturbances
  • Initially aggression will subside w the D2 blockers (we dont’ often use 1st gen but in acute phase we use them esp for acute aggression)*
  • Takes time to work effectively -> v difficult to treat -> sometimes hospitalizatin if harm to themselves*
38
Q

Typical Antipsychotics

MOA

A

D2 receptor antagonists (also block muscarininc, histamine, and a1 receptors) - Positive symptoms only

1st Gen: similar to TCAs they are nonselective -> also have tendency to bind to alot of receptors -> very sedating bc of histamine blockade, orthostatic hypotension nc of a1 receptors, anticholinergic

39
Q

Typical Antipsychotics

Agents

A
  • ​Phenothiazines

Chlorpromazine

Fluphenazine

  • Butyrophenones

Haloperidolol (Haldol)

We don’t really see typical (1st gens) used chronically, really for decompensated schiz when presenting with positive symptoms - aggression, psychosis, SI

40
Q

Haloperidol (Haldol)

Routes

A

Tablet

Injection

Solution

Depot

One time doses at hospital when ppl acting up

41
Q

Typical Antipsychotics

AE

A

Anticholinergic SE

Orthostatic hypotension

QTC prolongation

EPS

Hyperprolactinemia

42
Q

Atypical Antipsychotics

MOA

A

Block D2 receptors to a lesser extent vs. typicals and block 5HT-2A receptors

All may dissociate rapidly from D2 receptors (less EPS) and 5HT1 agonist (reduce glutamate release)

43
Q

Atypical Antipsychotics

Agents

A

Clozapine (Clozaril)

Olanzapine (Zyprexa)

Quetiapine (Seroquel)

Aripiprazole (Abilify)

Risperidone (Risperdal)

Lumateperone (Caplyta)

44
Q

Atypical Antipsychotics

Advantages (3)

Disadvantages (2)

A

Less sedation, movement disorders, tardive dyskinesia

More weight gain, metabolic disturbances

Less AE however more weight gain/metabolic dist. - this limitation maybe dt serotonin like phenomonen

45
Q

Atypical Antipsychotics

Indications

A

More long term management, more for negative symptoms

(will still help positive sx just to a lesser extent)

46
Q

In addition to blocking D2 receptors, typical antipsychotics also block muscarinic, histamine, and alpha 1 receptors. Which of the following is a potential SE when starting a typical antipsychotic?

  • Insomnia
  • Extrapyramidal symptoms
  • Hypertension
  • Hypersalivation
A

Extrapyramidal symptoms

47
Q

Aripiprazole (Abilify)

MOA

A

Partial D2 agonist, 5HT-1A agonist, 5HT-2A antagonist

What i want you to know is it CAN BE MIXED- partial D2 agonist = partially agonizing - we see a reduction in dopamine just not as pronounced as BLOCKING D2 receptors

48
Q

Aripiprazole (Abilify)

Routes

A
  • PO
  • IM depot Q4-6 wks
    • Aristada (newest formulation, 6 wks)
      • Must continue PO tx during first 3 wks of transitioning

IM depot useful for patients that are noncompliant

49
Q

Aripiprazole (Abilify)

Advantages

Can also be used for:

A

Less EPS and weight gain (may be better tolerated vs. others)

weight gain and QTC safe

BPD

50
Q

Atypical Antipsychotics
AE

  1. Cardiovascular (1)
    • less common with (1)
  2. Neurologic effects (1)
  3. Antcholinergic effects (3)
  4. Weight ____
    • greatest with (2)
  5. Impaired _____ tolerance
    • clear risk of __ __ in pts treated with ______ antipsychotics
    • Monitor serum _____
  6. Hematologic
    • (1) drug in particular may cause?
A
  1. QT Prolongation
    • Aripiprazole
  2. Sedation
  3. Dry mouth, urinary retention, constipation
  4. Gain
    • Clozapine, Olanzapine
  5. Glucose
    • DM, atypical
    • glucose
  6. Agranulocytosis
    • Clozapine -> need labs
51
Q

Lumateperone (Caplyta)

  • Simultaneously modulates s_____, d_____, and g_____ neurotransmission
  • ____ interaction with muscarininc, histamine, and alpha receptors (____ AE)
  • Placebo-controlled _____, sign. improvement in change of PANSS score (beginning in just one wk from start)
  • Significant imp in CGI-S score w ____ dose
  • Somnolence, sedation, constipation
  • ___ increase in suicidal ideation, EPS, weight changes, QTC prolongation
    • one seizure occured in one with hx of epilepsy (should be monitored closely)
  • Limitiations; Very ____ _____/______
    • Inclusion: ____ psychosis, previously:
    • Exclusion: e____, de_____, _____ disorder, >__yo, ___ history, _ _ _
A
  • serotonin, dopamine, glutamate
  • Lacks (less AE)
  • trial
  • increase
  • No
  • Specific Inclusion/Exclusion
    • Acute psyhocsis, previously responded to antipsychotic meds
    • epilepsy, depression, BD, >60yo, CV hx, HIV

“Dream drug” - targets what we want, doesn’t target what we don’t want - seemed promising but the issue is they were so specific with who they treated

52
Q

Boxed Warning - All Antipsychotics

A

Dementia: elderly pts with dementia related psychosis treated with antipsychotics increased risk of death

Most deaths appear to be either CV (HF, sudden death) or infectious (PNA)

53
Q

Bipolar Disorder

  • Recurrent episodes of ____, _____, and major ____ with _____ mood in between
A
  • Mania, Hypomania, Depression, Normal
    • Mania - distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least 1 wk
    • Hypomania - above, lasting for at least for days
    • Depression - major depressive disorder
54
Q

Lithium

Warnings/Contraindications

Increased risk of what?

A
  • Renal Insufficiency
  • Dehydration
  • Sodium Depletion

​INCREASED RISK OF TOXICITY dt decreased clearance

Lithium is like salt so if body is dehydrated/depleted its going to hold onto it

55
Q

Lithium

Significant Drug Interactions

A
  • NSAIDS
  • ACE Inhibitors and ARBS
  • Diuretics (cause sodium depletion -> decreased clearance again)

INCREASED RISK FOR TOXICTY dt INCREASED CONCENTRATIONS

56
Q

Lithium

Nursing Implication*

A

With such a narrow therapeutic window, we routinely monitor serum concentrations

57
Q

ST is a 50 yo male, long time pt of yours, properly managed on lithium for the management of his bipolar disorder. ST contacts you after sudden onset of nausea, vomiting, and impaired memory. What could be the cause of these symptoms?

  • ST has recently started taking ibuprofen (NSAID) 4 times/day for the management of new onset back pain
  • ST has recently stopped taking his diuretic
  • ST has recently replaced his second cup of coffee each day with a glass of water
  • All of the above
A
  • ST has recently started taking ibuprofen (NSAID) 4 times/day for management of new onset back pain
58
Q

If a patient is currently receiving warfarin (a CYP enzyme substrate) and is initiated on phenytoin, what do you expect to happen to pts INR and why?

  • The INR is expected to decrease bc phenytoin is an inhibitor of CYP enzymes
  • The INR is expected to increase bc phenytoin is an inducer of CYP enzymes
  • The INR is expected to remain the same
  • The INR is expected to decrease because phenytoin is an inducer of CYP enzymes
A
  • The INR is expected to decrease because phenytoin is an inducer of CYP enzymes
59
Q

Which of the following is TRUE regarding Carbamazepine?

  • Carbamazepine works by inhibiting GABA receptors
  • Patients of SE Asian and Chinese decent should be tested for HLA-B 1502 which is associated with an increased risk of hypersensitivity
  • Carbamazepine can be given IV
  • Carbamazepine can be used for generalized non-motor seizures
A
  • Patients of SE Asian and Chinese decent should be tested for HLA-B 1502 which is associated with an increased risk of hypersensitivity

Advanced Pharmacology (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions